Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.52 |
| ▸ | ESR1 | P03372 | 7/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL4491407 | 0.91 | CA12 (0.48) | ESR2ESR1MMP2MMP9CYP3A4 | |
| SCHEMBL5241008 | 0.90 | ESR2 (0.60) | ESR2ESR1MMP2MMP9LMNA | |
| SCHEMBL1495106 | 0.90 | ESR2 (0.54) | ESR2ESR1MMP2MMP9LMNA | |
| SCHEMBL1516123 | 0.88 | ESR2 (0.61) | ESR2ESR1MMP2MMP9LMNA | |
| SCHEMBL23977196 | 0.85 | ESR2 (0.41) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL19486880 | 0.84 | ESR2 (0.43) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL3682201 | 0.84 | ESR2 (0.39) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL27694968 | 0.83 | ESR2 (0.52) | ESR2ESR1MMP2MMP9HPGD | |
| SCHEMBL9322798 | 0.81 | ESR2 (0.50) | ESR2ESR1MMP2MMP9LMNA | |
| SCHEMBL21755391 | 0.80 | ESR2 (0.40) | ESR2ESR1MMP2MMP9OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-112105624-B | Treatment of cancer using (2, 2-dihydroxymethyl) methylene cyclopropane nucleotides | 美迪维尔公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| CN-112105624-A | Treatment of cancer using (2, 2-bis hydroxymethyl) methylene cyclopropane nucleotides | 美迪维尔公司 | 2020-12-18 | — | — | CN | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | ESR2 767/4885ESR1 3357/4885MMP2 411/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | ESR2 1166/4885ESR1 1065/4885MMP2 4748/4885 |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ESR2 1223/4885ESR1 2306/4885MMP2 2887/4885 |
| US-20070275946-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | ESR2 2703/4885ESR1 4686/4885MMP2 160/4885 |
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | ESR2 717/4885ESR1 2540/4885MMP2 482/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ESR2 1490/4885ESR1 2778/4885MMP2 2226/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ESR2 1223/4885ESR1 2306/4885MMP2 2887/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ESR2 1220/4885ESR1 1274/4885MMP2 4752/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ESR2 1220/4885ESR1 1274/4885MMP2 4752/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | ESR2 1220/4885ESR1 1274/4885MMP2 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.